28.91
0.55 (1.94%)
| Previous Close | 28.36 |
| Open | 28.31 |
| Volume | 117,610 |
| Avg. Volume (3M) | 177,676 |
| Market Cap | 1,741,540,480 |
| Price / Book | 268.22 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -15.40 |
| Total Debt/Equity (MRQ) | 0.53% |
| Current Ratio (MRQ) | 9.62 |
| Operating Cash Flow (TTM) | -15.13 M |
| Levered Free Cash Flow (TTM) | -8.59 M |
| Return on Assets (TTM) | -35.94% |
| Return on Equity (TTM) | -88.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Galecto, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.69% |
| % Held by Institutions | 13.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jain Global Llc | 31 Dec 2025 | 120,566 |
| Remedium Capital Partners, Llc | 31 Dec 2025 | 120,473 |
| Sigma Planning Corp | 31 Dec 2025 | 14,500 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (Leerink Partners, 59.11%) | Buy |
| Median | 45.00 (55.66%) | |
| Low | 40.00 (Guggenheim, 38.36%) | Buy |
| Average | 43.67 (51.06%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 26.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 17 Feb 2026 | 40.00 (38.36%) | Buy | 29.91 |
| UBS | 17 Feb 2026 | 45.00 (55.66%) | Buy | 29.91 |
| Leerink Partners | 07 Jan 2026 | 46.00 (59.11%) | Buy | 21.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones |
| 06 Jan 2026 | Announcement | Galecto Announces Key Additions to Leadership Team |
| 16 Dec 2025 | Announcement | Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |